CD276 and small cell lung carcinoma: Notably, a recent study by Johnson and colleagues reported promising outcomes with ifinatamab deruxtecan, a novel ADC combining B7-H3 targeting and topoisomerase inhibition, achieving objective response rates of up to 52% in small cell lung cancer (SCLC) [33].